Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
valuation ratios | |
|---|---|
| pe ratio | 18.16 |
| peg ratio | -1.35 |
| price to book ratio | 15.74 |
| price to sales ratio | 7.54 |
| enterprise value multiple | 10.16 |
| price fair value | 15.74 |
profitability ratios | |
|---|---|
| gross profit margin | 78.34% |
| operating profit margin | 50.35% |
| pretax profit margin | 50.68% |
| net profit margin | 41.43% |
| return on assets | 18.53% |
| return on equity | 156.4% |
| return on capital employed | 23.74% |
liquidity ratio | |
|---|---|
| current ratio | 10.36 |
| quick ratio | 9.15 |
| cash ratio | 1.42 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 233.77 |
| operating cycle | 343.86 |
| days of payables outstanding | 22.05 |
| cash conversion cycle | 321.80 |
| receivables turnover | 3.32 |
| payables turnover | 16.55 |
| inventory turnover | 1.56 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.71 |
| debt equity ratio | 3.32 |
| long term debt to capitalization | 0.77 |
| total debt to capitalization | 0.77 |
| interest coverage | 25.41 |
| cash flow to debt ratio | 0.27 |
cash flow ratios | |
|---|---|
| free cash flow per share | 3.10 |
| cash per share | 5.25 |
| operating cash flow per share | 3.18 |
| free cash flow operating cash flow ratio | 0.97 |
| cash flow coverage ratios | 0.27 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | 39.35 |
Frequently Asked Questions
Halozyme Therapeutics, Inc. (HALO) published its most recent earnings results on 31-10-2024.
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Halozyme Therapeutics, Inc. (NASDAQ:HALO)'s trailing twelve months ROE is 156.4%.
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Halozyme Therapeutics, Inc. (HALO) currently has a ROA of 18.53%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
HALO reported a profit margin of 41.43% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
Apple's current ratio, which measures its ability to pay short-term obligations, was 10.36 in the most recent quarter. The quick ratio stood at 9.15, with a Debt/Eq ratio of 3.32.